QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
NASDAQ:CVET

Covetrus - CVET Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$20.99
$20.99
50-Day Range
$20.87
$20.99
52-Week Range
$13.39
$21.20
Volume
3 shs
Average Volume
1.34 million shs
Market Capitalization
$2.94 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00
CVET stock logo

About Covetrus (NASDAQ:CVET) Stock

Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions, such as inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software, data-driven applications, client communications tools, and related services to increase staff efficiency and enhance business health; and solutions that integrate with its software platforms, including client communication services, reminders, data backup services, hardware sales and support, and credit card processing services for veterinary practitioners and animal-health clinics. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as offers shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal, equine, and large-animal markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine. As of October 13, 2022, Covetrus, Inc. was taken private.

Receive CVET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Covetrus and its competitors with MarketBeat's FREE daily newsletter.

CVET Stock News Headlines

“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Covetrus, Inc. (CVET)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Covetrus Names Michelle Bonfilio as Chief People Officer
Covetrus Names Margie B. Pritchard General Counsel
Covetrus Announces Retirement of Matthew Foulston
Form PRER14A COVETRUS, INC. - StreetInsider.com
See More Headlines
Receive CVET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Covetrus and its competitors with MarketBeat's FREE daily newsletter.

CVET Company Calendar

Last Earnings
2/28/2021
Today
2/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Drug Stores & Proprietary Stores
Sub-Industry
N/A
Current Symbol
NASDAQ:CVET
Fax
N/A
Employees
5,710
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.00
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
-4.7%
Consensus Rating
Hold
Rating Score (0-4)
1.83
Research Coverage
6 Analysts

Profitability

Net Income
$-54,000,000.00
Pretax Margin
-0.56%

Debt

Sales & Book Value

Annual Sales
$4.58 billion
Cash Flow
$2.19 per share
Book Value
$10.97 per share

Miscellaneous

Free Float
139,563,000
Market Cap
$2.94 billion
Optionable
Not Optionable
Beta
1.51

Key Executives

  • Mr. Benjamin WolinMr. Benjamin Wolin (Age 46)
    Pres, CEO & Director
    Comp: $1.02M
  • Mr. Matthew J. Foulston (Age 57)
    Exec. VP & Global CFO
    Comp: $624.66k
  • Ms. Georgina Wraight (Age 47)
    Exec. VP & Pres of Global Technology Solutions
    Comp: $563.4k
  • Mr. Matthew Malenfant (Age 60)
    Chief Commercial Officer
    Comp: $533.62k
  • Ms. Rebecca Kidd (Age 53)
    Head of Operations & Operational Excellence
  • Mr. Andrew B. Coxhead (Age 53)
    VP, Corp. Controller & Chief Accounting Officer
  • Mr. Nicholas Michael Jansen
    VP of Investor Relations
  • Ms. Margie B. Pritchard
    Gen. Counsel & Corp. Sec.
  • Mr. Cameron R. Foster
    Sr. VP of Strategy & Corp. Devel.
  • Ms. Michelle Bonfilio (Age 51)
    Chief People Officer













CVET Stock - Frequently Asked Questions

Should I buy or sell Covetrus stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Covetrus in the last year. There are currently 1 sell rating and 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CVET shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVET, but not buy additional shares or sell existing shares.
View CVET analyst ratings
or view top-rated stocks.

What is Covetrus' stock price forecast for 2023?

6 equities research analysts have issued 1 year price targets for Covetrus' stock. Their CVET share price forecasts range from $16.00 to $22.00. On average, they predict the company's share price to reach $20.00 in the next twelve months. This suggests that the stock has a possible downside of 4.7%.
View analysts price targets for CVET
or view top-rated stocks among Wall Street analysts.

How were Covetrus' earnings last quarter?

Covetrus, Inc. (NASDAQ:CVET) issued its earnings results on Sunday, February, 28th. The company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.16 by $0.05. The business earned $1.12 billion during the quarter, compared to the consensus estimate of $1.06 billion. Covetrus had a positive trailing twelve-month return on equity of 6.83% and a negative net margin of 0.28%. The business's revenue was up 11.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.18 earnings per share.

What is Benjamin Wolin's approval rating as Covetrus' CEO?

25 employees have rated Covetrus Chief Executive Officer Benjamin Wolin on Glassdoor.com. Benjamin Wolin has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Covetrus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Covetrus investors own include Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), AT&T (T), Activision Blizzard (ATVI), Boeing (BA), Chegg (CHGG), Enphase Energy (ENPH), Enterprise Products Partners (EPD) and Livongo Health (LVGO).

What is Covetrus' stock symbol?

Covetrus trades on the NASDAQ under the ticker symbol "CVET."

Who are Covetrus' major shareholders?

Covetrus' stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Anthony C Jr Providenti, Benjamin Wolin, David Stuart Hinton, Dustin Finer, Edward Mcnamara, Georgina Wraight, Herbert Virgin, Laura J Phillips, Michael Ellis and Timothy Ludlow.
View institutional ownership trends
.

What is Covetrus' stock price today?

One share of CVET stock can currently be purchased for approximately $20.99.

How much money does Covetrus make?

Covetrus (NASDAQ:CVET) has a market capitalization of $2.94 billion and generates $4.58 billion in revenue each year. The company earns $-54,000,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis.

How many employees does Covetrus have?

The company employs 5,710 workers across the globe.

How can I contact Covetrus?

Covetrus' mailing address is 7 CUSTOM HOUSE STREET, PORTLAND ME, 04101. The official website for the company is www.henryscheinvet.com. The company can be reached via phone at (888) 280-2221 or via email at nicholas.jansen@covetrus.com.

This page (NASDAQ:CVET) was last updated on 2/3/2023 by MarketBeat.com Staff